Relationships between the concentrations of prostaglandins and the nonsteroidal antiinflammatory drugs indomethacin, diclofenac, and ibuprofen

Pharmacotherapy

Volumn 25, Issue 1, 2005, Pages 18-25

  Giagoudakis, George ^a   Markantonis, Sophia L ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

NSAIDs; Plasma concentrations; Prostaglandin E2 metabolite (PGEM) concentrations

Indexed keywords

13,14 DIHYDRO 15 OXOPROSTAGLANDIN E2; DICLOFENAC; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; KETOPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN; REUMACID;

ADULT; ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG EFFECT; DRUG POTENCY; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

ADMINISTRATION, ORAL; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CAPSULES; CROSS-OVER STUDIES; DICLOFENAC; DINOPROSTONE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IBUPROFEN; INDOMETHACIN; MALE; TABLETS; TIME FACTORS;

EID: 11144243813     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.25.1.18.55618     Document Type: Article

References (22)

1. Heller CA, Ingelfinger JA, Goldman P. Nonsteroidal antiinflammatory drugs and aspirin-analyzing the scores. Pharmacotherapy 1985;5:30-8.
2. British Medical Association and Royal Pharmaceutical Society of Great Britain. British national formulary (BNF 48). London, UK, 2004.
3. Baber N, Halliday LD, Van Den Heuvel WJ, et al. Indomethacin in rheumatoid arthritis: clinical effects, pharmacokinetics and platelet studies in responders and non-responders. Ann Rheum Dis 1979;38:128-36.
4. Capell HA, konetschnik B, Glass RC. Anti-inflammatory analgesic drug responders an non-responders: a clinico-pharmacological study of flurbiprofen. Br J Clin Pharmacol 1977;4:623-4.
5. Davies NM, Skjodt NM. Choosing the right nonsteroidal anti-inflammatory drug for the right patient: a pharmacokinetic approach. Clin Phannacokin 2000;38(5):377-92.
6. Seppala E, Nissila M, Isomaki H, et al. Comparison of the effects of different anti-inflammatory drugs on synovial fluid prostanoid concentrations in patients with rheumatoid arthritis. Clin Rheumatol 1985;4(3):315-20.
7. Cox SR, Venderlugt JT, Gumbleton TJ, Smith RB. Relationships between thromboxane production, platelet aggregability, and serum concentrations of ibuprofen or flurbiprofen. Clin Pharmacol Ther 1987;41:510-21.
8. Evans AM, Nation KL, Sansom LN, Bochner F, Somogyi AA. Effect of racemic ibuprofen dose on the magnitude and duration of platelet cyclo-oxygenase inhibition: relationship between inhibition of thromboxane production and plasma unbound concentration of S(+)-ibuprofen. Br J Clin Pharmacol 1991;31,131-8.
9. Ronni-Sivula H, Malm H, Ylikorkola O, Viinikka L. Marathon run stimulates more prostacyclin than thromboxane synthesis and differently in men and women. Prostaglandins 1993;46:75-9.
10. Morrow JD, Harris TM, Roberts LJ II. Noncyclooxygenase oxidative formation of a series of novel prostaglandins: analytical ramifications for measurement of eicosanoids. Anal Biochem 1990;184:1-10.
11. Morrow JD, Roberts LJ II. Quantification of noncyclooxygenase derived prostanoids as a marker of oxidative stress. Free Radic Biol Med 1991;10:195-200.
12. Nielsen-Kudsk F. HPLC-determination of some antiinflammatory, weak analgesic and uricosuric drugs in human blood plasma and its application to pharmacokinetics. Acta Pharmacol Toxicol 1980;15:267-73.
13. Giagoudakis G, Markantonis SL. An alternative high-performance liquid-chromatographic method for the determination of diclofenac and flurbiprofen in plasma. J Pharm Biomed Anal 1998;17:897-901.
14. Demers LM, Brennecke SP, Mountford LA, Brunt JD, Turnbull AC. Development and validation of a radioimmunoassay for prostaglandin E2 metabolite levels in plasma. J Clin Endocrinol Metab 1983;57(1):101-6.
15. Thompson PJ, Greenough A, Nicolaides KH, Lopez-Bernal A. Elevation of prostaglandin levels in pregnancies complicated by premature rupture of the membranes. J Perinat Med 1992;20:5-9.
16. Parfitt K, ed. Martindale: The complete drug reference, 32nd edition. London, UK: Pharmaceutical Press, 1999:32, 44, 46.
17. Oliw E, Lunden I, Anggard E. In vivo inhibition of prostaglandin synthesis in rabbit kidney by nonsteroidal antiinflammatory drugs. Acta Pharmacol Toxicol 1978;42:179-84.
18. Vetrugno M, Maineo A, Quaranta GM, Cardia L. A randomised, double-masked, clinical study of the efficacy of four NSAIDs in pain control after excimer laser photorefractive keratectomy. Clin Ther 2000;22(6):719-31.
19. Gotzsche PC. Review of dose-response studies of NSAIDs in rheumatoid arthritis. Dan Med Bull 1989;36(4):395-9.
20. Day RO, Graham GG, Williams KM, Brooks PM. Variability in response to NSAIDs: fact or fiction? Drugs 1988;36:643-51.
21. Cassidy J, Berner B, Chan K, et al. Human transbuccal absorption of diclofenac sodium from a prototype hydrogel delivery device. Pharm Res 1993;10(1):126-9.
22. Davies NM, Andersen KE. Clinical pharmacokinetics of diclofenac: therapeutic insights and pitfalls. Clin Pharmacokin 1997;33(3):184-213.